Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine Plus Gemtuzumab Ozogamicin in Older Patients With Untreated Non-M3 AML
NCT00658814Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2008
- Primary completion
- Jun 2013
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoints: Complete Response at 60 days and 30-Day Survival. Started Dec 2008; status: active, not recruiting.
02
Drugs
azacitidinegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00658814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658814.